|
Back to Home » October 2019 News » Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum |
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum |
October 02, 2019
EAST HANOVER, N.J., Oct. 2, 2019 /PRNewswire/ -- Novartis, a leader in rheumatology and immuno-dermatology, today announced additional positive data from the PREVENT trial, evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with non-radiographic axial...
Source URL: https://www.prnewswire.com:443/news-releases/novartis-positive-52-week-prevent-data-confirm-cosentyx-efficacy-in-addressing-entire-axspa-spectrum-300929426.html
|
|
|
|
